Founded in 1992 and listed in 2015, Wondfo is a fast-growing biotechnology company in China. Wondfo mainly focuses on rapid diagnostics in China but is looking for further development in other areas of the healthcare industry. Besides the headquarter in Guangzhou, Wondfo also owns 2 overseas labs, 1 branch in Chicago, and 11 overseas offices. After many years’ efforts in delivering high-quality products and services, Wondfo has won a good reputation around the world. In production, Wondfo strictly complies with national and international regulations and standards. We have got CE certificates, FDA certificates, FSC certificates, ISO 9001:2008, and ISO 13485:2012 quality system certification. Wondfo attaches great importance to research and development and sees innovation as the soul of the enterprise’s development. So far, Wondfo has 530+ highly-qualified researchers and over 30% of the staff have obtained master's and doctorate degrees from prestigious universities worldwide. Wondfo also has built R&D laboratories in Guangzhou and San Diego. With our advanced production lines and highly experienced staff, Wondfo’s daily production capacity of test kits reaches 1.5 million. Wondfo also provides a number of customized services to professional distributors and partnering affiliates. Wondfo provides high-quality products at a very competitive price, together with professional technical support and counseling service. Currently, Wondfo has customers in more than 150 countries and areas. It is our commitment to safeguarding the health and improving lives with better products, services, and solutions. With more than 3000 dedicated employees, we'll continue to innovate and shape the future of POCT and healthcare.
Looking for a particular Wondfo employee's phone or email?
The Wondfo annual revenue was $16.8 million in 2026.
Ann Wang is the CFO of Wondfo.
138 people are employed at Wondfo.
Wondfo is based in Guangzhou, Guangdong.
The NAICS codes for Wondfo are [325413, 3254, 32, 325, 32541].
The SIC codes for Wondfo are [283, 28].